Abstract:
Improved progression-free survival (PFS) in CRC pts has been observed using a modified 2-week CO schedule [Scheithauer et al. J Clin Oncol 2003;21:1307– 12] and the TREE-2 study indicated that B adds little toxicity to these drugs [Hochster et al. J Clin Oncol 2006;24(18S):3510]. This phase II study determined the feasibility of the combination C (1.75g/m2 BD days 1-7), O and B using a 14-day cycle for pts with advanced, unresectable CRC.